Clinical Trial Protocol Skill
A clinical trial protocol stands or falls on a few linked decisions: a clear objective, a design that can answer
it, endpoints that measure it, eligibility that defines who's studied, and a statistical plan that can detect the
effect. This skill drafts a protocol synopsis that makes those decisions explicit and internally consistent, in
the structure IRBs/ethics committees and regulators expect. (For a general academic or UX study, use
research-protocol.)
Safety & compliance note: this is a drafting aid for expert review, not regulatory, medical, or
statistical sign-off. Real trials require qualified investigators, a statistician, and IRB/ethics and
regulatory approval (e.g. GCP, ICH, local law). Do not invent efficacy/safety data; mark assumptions for the
study team to set.
Working from a brief
Given "a phase II trial of drug X for condition Y", produce the full synopsis anyway — infer a defensible
design, endpoints, and eligibility appropriate to the phase and condition, and clearly label every inferred
choice as a draft assumption for the study team and statistician to confirm. Never fabricate prior data or
effect sizes; state them as placeholders to be set.
Required Inputs
Ask for these only if they aren't already provided (else infer and label as draft):
- Intervention & condition — what's being studied, in whom, and the phase.
- Objective / question — the primary question the trial must answer.
- Comparator — placebo, standard of care, or active control; and blinding.
- Outcome of interest — how benefit (and harm) will be measured.
- Constraints — known population, setting, and any regulatory context.
Output Format
Clinical Trial Protocol Synopsis: [title]
- 1. Background & rationale — the problem, prior evidence (mark placeholders), and why this trial.
- 2. Objectives — primary and secondary, each as a precise, testable statement.
- 3. Design — phase, type (RCT, etc.), allocation/randomisation, blinding, arms, and duration.
- 4. Population — setting, and explicit inclusion and exclusion criteria.
- 5. Interventions — the intervention and comparator: dose/regimen, administration, and concomitant rules.
- 6. Endpoints — primary endpoint (one, tied to the primary objective), secondary endpoints, and how/when each is measured.
- 7. Statistical considerations — analysis populations, the primary analysis, and a sample-size basis (with assumptions flagged for the statistician).
- 8. Safety — adverse-event definitions, monitoring/reporting, stopping rules, and any DSMB.
- 9. Ethics & conduct — informed consent, IRB/ethics approval, data integrity, and GCP adherence.
Close with assumptions to confirm and a reminder that a qualified investigator and statistician must own the final protocol.
Quality Checks
Anti-Patterns
Based On
Clinical research practice — objective-endpoint-analysis alignment, explicit eligibility, sample-size justification, and ICH-GCP safety/ethics structure.
1---2name: clinical-trial-protocol-23description: "Draft a clinical trial protocol synopsis with the elements regulators and IRBs expect. Use when asked to write a clinical trial protocol, a study protocol synopsis, a trial design, or to structure endpoints/eligibility/statistics for an interventional study. Produces a structured protocol synopsis — objectives, design, population with eligibility, interventions, endpoints, statistics, and safety/ethics — for expert review. (For non-clinical/UX research, use research-protocol.)"4homepage: https://mohitagw15856.github.io/pm-claude-skills/skill/clinical-trial-protocol.html5metadata:6 source: https://skillmd.com/skills/mohitagw15856/clinical-trial-protocol-27 openclaw:8 emoji: 🩺9---1011# Clinical Trial Protocol Skill1213A clinical trial protocol stands or falls on a few linked decisions: a clear objective, a design that can answer14it, endpoints that measure it, eligibility that defines who's studied, and a statistical plan that can detect the15effect. This skill drafts a protocol synopsis that makes those decisions explicit and internally consistent, in16the structure IRBs/ethics committees and regulators expect. (For a general academic or UX study, use17[`research-protocol`](../research-protocol/SKILL.md).)1819> **Safety & compliance note:** this is a drafting aid for **expert review**, not regulatory, medical, or20> statistical sign-off. Real trials require qualified investigators, a statistician, and IRB/ethics and21> regulatory approval (e.g. GCP, ICH, local law). Do not invent efficacy/safety data; mark assumptions for the22> study team to set.2324## Working from a brief2526Given "a phase II trial of drug X for condition Y", **produce the full synopsis anyway** — infer a defensible27design, endpoints, and eligibility appropriate to the phase and condition, and clearly label every inferred28choice as a draft assumption for the study team and statistician to confirm. Never fabricate prior data or29effect sizes; state them as placeholders to be set.3031## Required Inputs3233Ask for these only if they aren't already provided (else infer and label as draft):3435- **Intervention & condition** — what's being studied, in whom, and the phase.36- **Objective / question** — the primary question the trial must answer.37- **Comparator** — placebo, standard of care, or active control; and blinding.38- **Outcome of interest** — how benefit (and harm) will be measured.39- **Constraints** — known population, setting, and any regulatory context.4041## Output Format4243### Clinical Trial Protocol Synopsis: [title]4445- **1. Background & rationale** — the problem, prior evidence (mark placeholders), and why this trial.46- **2. Objectives** — primary and secondary, each as a precise, testable statement.47- **3. Design** — phase, type (RCT, etc.), allocation/randomisation, blinding, arms, and duration.48- **4. Population** — setting, and explicit **inclusion** and **exclusion** criteria.49- **5. Interventions** — the intervention and comparator: dose/regimen, administration, and concomitant rules.50- **6. Endpoints** — **primary endpoint** (one, tied to the primary objective), secondary endpoints, and how/when each is measured.51- **7. Statistical considerations** — analysis populations, the primary analysis, and a sample-size basis (with assumptions flagged for the statistician).52- **8. Safety** — adverse-event definitions, monitoring/reporting, stopping rules, and any DSMB.53- **9. Ethics & conduct** — informed consent, IRB/ethics approval, data integrity, and GCP adherence.5455Close with **assumptions to confirm** and a reminder that a qualified investigator and statistician must own the final protocol.5657## Quality Checks5859- [ ] The primary objective, primary endpoint, and primary analysis are aligned and consistent60- [ ] There is exactly one primary endpoint, clearly measurable and time-anchored61- [ ] Inclusion/exclusion criteria are explicit and operationally checkable62- [ ] Sample-size basis is stated with its assumptions flagged for the statistician63- [ ] Safety monitoring, reporting, and stopping rules are present64- [ ] Ethics/consent/IRB and GCP elements are included; no efficacy/safety data is invented6566## Anti-Patterns6768- [ ] Do not invent prior efficacy/safety data or effect sizes — mark them as placeholders to be set69- [ ] Do not list multiple "primary" endpoints — pick one and demote the rest to secondary70- [ ] Do not let objective, endpoint, and analysis drift apart — they must answer the same question71- [ ] Do not present this as regulatory/statistical sign-off — it's a draft for expert review72- [ ] Do not omit safety monitoring and stopping rules — a protocol without them isn't approvable7374## Based On7576Clinical research practice — objective-endpoint-analysis alignment, explicit eligibility, sample-size justification, and ICH-GCP safety/ethics structure.